Transgender individuals tend to be less physically active than cisgender individuals, and the primary focus of these physical activity barriers have been psychosocial in nature. Very little attention has been given to the role that changes in the sex hormone milieu (such as that occurring during gender-affirming hormone therapy) play on physical activity. The purpose of this study was to explore the effects of sex hormone suppression using a gonadotropin-releasing hormone agonist (GnRHa) on physical activity levels and patterns.
Methods:
Female and male rats received 4 weeks of sex hormone suppression using the GnRHa goserelin acetate (GA) or received a placebo as a control (CON). Animals were then allowed free access to voluntary running wheels, and activity was recorded throughout the treatment period.
Results:
Female rats receiving GA (F GA) had a significantly lower total wheel running distance than female CON (F CON, 53±11 km vs. 113±28 km, respectively, p=0.042), and male rats receiving GA (M GA) had a significantly lower total wheel running distance when compared with male CON (M CON, 31±7 km vs. 69±18 km, respectively, p=0.037). Differences in daily wheel running distances were first observed at day 18 between F GA and F CON (p=0.037) and at day 2 between M GA and M CON (p=0.021).
Conclusion:
Reduced sex hormone availability reduced wheel running activity in female and male rats. Understanding the role that sex hormone manipulation has on physical activity may be an important consideration in promoting physical activity in transgender individuals receiving treatments that reduce sex hormone availability.
Get full access to this article
View all access options for this article.
References
1.
Institute of Medicine. The Health of Lesbian, Bisexual, and Transgender People: Building a Foundation for Better Understanding. Washington, DC: National Academies Press, 2011.
2.
Clements-NolleK, MarxR, GuzmanR, KatzM. HIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: implications for public health intervention. Am J Public Health. 2001; 91:915–921.
3.
Clements-NolleK, MarxR, KatzM. Attempted suicide among transgender persons: the influence of gender-based discrimination and victimization. J Homosex. 2006; 51:53–69.
4.
WitcombGL, BoumanWP, ClaesL, et al.Levels of depression in transgender people and its predictors: results of a large matched control study with transgender people accessing clinical services. J Affect Disord. 2018; 235:308–315.
5.
MustanskiB, LiuRT. A longitudinal study of predictors of suicide attempts among lesbian, gay, bisexual, and transgender youth. Arch Sex Behav. 2013; 42:437–448.
6.
Fernández-RoucoN, CarcedoRJ, LópezF, OrgazMB. Mental health and proximal stressors in transgender men and women. J Clin Med. 2019; 8:413.
7.
DowningJM, PrzedworskiJM. Health of transgender adults in the U.S., 2014–2016. Am J Prev Med. 2018; 55:336–344.
8.
StreedCG, HarfouchO, MarvelF, et al.Cardiovascular disease among transgender adults receiving hormone therapy: a narrative review. Ann Intern Med. 2017; 167:256–267.
9.
CaceresBA, JackmanKB, EdmondsonD, BocktingWO. Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014–2017 BRFSS. J Behav Med. 2020; 43:329–338.
10.
AlzahraniT, NguyenT, RyanA, et al.Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes. 2019; 12:e005597.
11.
Fredriksen-GoldsenKI, Cook-DanielsL, KimHJ, et al.Physical and mental health of transgender older adults: an at-risk and underserved population. Gerontologist. 2014; 54:488–500.
12.
ConnellyPJ, Marie FreelE, PerryC, et al.Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults. Hypertension. 2019; 74:1266–1274.
13.
BudgeSL, AdelsonJL, HowardKA. Anxiety and depression in transgender individuals: the roles of transition status, loss, social support, and coping. J Consult Clin Psychol. 2013; 81:545–557.
14.
MuellerA, KiesewetterF, BinderH, et al.Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab. 2007; 92:3470–3475.
15.
EmiY, AdachiM, SasakiA, et al.Increased arterial stiffness in female-to-male transsexuals treated with androgen. J Obstet Gynaecol Res. 2008; 34:890–897.
16.
GulanskiBI, FlanneryCA, PeterPR, et al.Compromised endothelial function in transgender men taking testosterone. Clin Endocrinol (Oxf). 2020; 92:138–144.
17.
KellyDM, JonesTH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013; 217:R25–R45.
18.
PastuszakAW, KohnTP, EstisJ, LipshultzLI. Low plasma testosterone is associated with elevated cardiovascular disease biomarkers. J Sex Med. 2017; 14:1095–1103.
19.
HydockDS, WondersKY, SchneiderCM, HaywardR. Androgen deprivation therapy and cardiac function: effects of endurance training. Prostate Cancer Prostatic Dis. 2006; 9:392–398.
20.
LuYL, KuangL, ZhuH, et al.Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5alpha-reductase inhibitor. Asian J Androl. 2007; 9:843–847.
21.
RyuSJ, RyuDS, KimJY, et al.Bone mineral density changes after orchiectomy using a scrotal approach in rats. Korean J Spine. 2015; 12:55–59.
22.
NaftolinF, FriedenthalJ, NachtigallR, NachtigallL. Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment. F1000Res. 2019; 8:F1000 Faculty Rev-1576.
23.
FaubionSS, KuhleCL, ShusterLT, RoccaWA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric. 2015; 18:483–491.
24.
ScheerJR, PachankisJE. Psychosocial syndemic risks surrounding physical health conditions among sexual and gender minority individuals. LGBT Health. 2019; 6:377–385.
25.
White HughtoJM, ReisnerSL, PachankisJE. Transgender stigma and health: a critical review of stigma determinants, mechanisms, and interventions. Soc Sci Med. 2015; 147:222–231.
26.
DubinSN, NolanIT, StreedCG, et al.Transgender health care: improving medical students' and residents' training and awareness. Adv Med Educ Pract. 2018; 9:377–391.
27.
BlosnichJR, RodriguezKL, HruskaKL, et al.Utilization of the Veterans Affairs' Transgender E-consultation Program by Health Care Providers: Mixed-Methods Study. JMIR Med Inform. 2019; 7:e11695.
28.
CarekPJ, LaibstainSE, CarekSM. Exercise for the treatment of depression and anxiety. Int J Psychiatry Med. 2011; 41:15–28.
29.
LanierJB, BuryDC, RichardsonSW. Diet and physical activity for cardiovascular disease prevention. Am Fam Physician. 2016; 93:919–924.
30.
LugoD, PulidoAL, MihosCG, et al.The effects of physical activity on cancer prevention, treatment and prognosis: a review of the literature. Complement Ther Med. 2019; 44:9–13.
31.
AuneD, NoratT, LeitzmannM, et al.Physical activity and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis. Eur J Epidemiol. 2015; 30:529–542.
32.
JonesBA, HaycraftE, BoumanWP, ArcelusJ. The levels and predictors of physical activity engagement within the treatment-seeking transgender population: a matched control study. J Phys Act Health. 2018; 15:99–107.
33.
LucassenMF, GuntupalliAM, ClarkT, et al.Body size and weight, and the nutrition and activity behaviours of sexual and gender minority youth: findings and implications from New Zealand. Public Health Nutr. 2019; 22:2346–2356.
34.
MuchickoMM, LeppA, BarkleyJE. Peer victimization, social support and leisure-time physical activity in transgender and cisgender individuals. Leisure/Loisir. 2014; 38:295–308.
35.
JonesBA, ArcelusJ, BoumanWP, HaycraftE. Barriers and facilitators of physical activity and sport participation among young transgender adults who are medically transitioning. Int J Transgend. 2017; 18:227–238.
36.
HydockDS, LienCY, SchneiderCM, HaywardR. Effects of voluntary wheel running on cardiac function and myosin heavy chain in chemically gonadectomized rats. Am J Physiol Heart Circ Physiol. 2007; 293:H3254–H3264.
37.
HydockDS, IwaniecUT, TurnerRT, et al.Effects of voluntary wheel running on goserelin acetate-induced bone degeneration. Pathophysiology. 2008; 15:253–259.
38.
FurrBJ.Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex. Horm Res. 1989; 32Suppl 1:86–92.
39.
SchmidB, Helfrich-FörsterC, YoshiiT. A new ImageJ plug-in “ActogramJ” for chronobiological analyses. J Biol Rhythms. 2011; 26:464–467.
40.
ChenH, GaoL, YangD, et al.Coordination between the circadian clock and androgen signaling is required to sustain rhythmic expression of Elovl3 in mouse liver. J Biol Chem. 2019; 294:7046–7056.
41.
PerrinJS, SegallLA, HarbourVL, et al.The expression of the clock protein PER2 in the limbic forebrain is modulated by the estrous cycle. Proc Natl Acad Sci U S A. 2006; 103:5591–5596.
42.
McGinnisMY, LumiaAR, TetelMJ, et al.Effects of anabolic androgenic steroids on the development and expression of running wheel activity and circadian rhythms in male rats. Physiol Behav. 2007; 92:1010–1018.
43.
HagenauerMH, KingAF, PossidenteB, et al.Changes in circadian rhythms during puberty in Rattus norvegicus: developmental time course and gonadal dependency. Horm Behav. 2011; 60:46–57.
44.
HashimotoA, FujikiS, NakamuraW, NakamuraTJ. Effects of testosterone on circadian rhythmicity in old mice. J Physiol Sci. 2019; 69:791–798.
45.
Juarez-TapiaC, Miranda-AnayaM. Ovariectomy influences the circadian rhythm of locomotor activity and the photic phase shifts in the volcano mouse. Physiol Behav. 2017; 182:77–85.
46.
DittrichR, BinderH, CupistiS, et al.Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes. 2005; 113:586–592.
47.
HembreeWC, Cohen-KettenisPT, GoorenL, et al.Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017; 102:3869–3903.
48.
ChewD, AndersonJ, WilliamsK, et al.Hormonal treatment in young people with gender dysphoria: a systematic review. Pediatrics. 2018; 141:e20173742.
49.
T'SjoenG, ArcelusJ, GoorenL, et al.Endocrinology of transgender medicine. Endocr Rev. 2019; 40:97–117.
50.
BowenRS, KnabAM, HamiltonAT, et al.Effects of supraphysiological doses of sex steroids on wheel running activity in mice. J Steroids Horm Sci. 2012; 3:110.
51.
BuniamJ, ChukijrungroatN, KhamphayaT, et al.Estrogen and voluntary exercise attenuate cardiometabolic syndrome and hepatic steatosis in ovariectomized rats fed a high-fat high-fructose diet. Am J Physiol Endocrinol Metab. 2019; 316:E908–E921.
52.
MeyerIH, BrownTN, HermanJL, et al.Demographic characteristics and health status of transgender adults in select US regions: behavioral risk factor surveillance system, 2014. Am J Public Health. 2017; 107:582–589.
53.
WierckxK, ElautE, DeclercqE, et al.Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol. 2013; 169:471–478.
54.
GorczynskiPF, BrittainDR. Call to action: the need for an LGBT-focused physical activity research strategy. Am J Prev Med. 2016; 51:527–530.
